drugset / Trial / NCT03001076

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

NCT03001076

Phase 3 Completed 269 enrolled Esperion Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

Timeline

Start
2016-11-29
Primary completion
2018-01-11
Completion
2018-02-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 180 mg Oral
Background Ezetimibe Unknown 10 mg